Atlas Trials

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

Clinical trial NCT03661554 · UNKNOWN

Trial details

NCT number
NCT03661554
Sponsor
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Relapsed and Refractory Multiple Myeloma
Start date
2018-04-10
Primary completion
2018-10-30
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.